Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Hypertrophic chondrocytes are deeply involved in the growth of mammalian bones. Researchers find that these cells transform into multiple functional cell types, including those responsible for ...

Tea and coffee are two of the most popular drinks in the world – daily rituals linked to culture, comfort, and productivity.

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine at the University of ...

Osteoblasts act in a group to make bone over the course of several months. However, how osteoblasts cooperate with each other in vivo is still unknown. Now, researchers at Osaka University established ...

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to ...

Skeletal conditions such as developmental dysplasia of the hip (DDH), osteoporosis, and osteoarthritis affect millions worldwide, often causing chronic pain and disability. These disorders stem from ...

Ultragenyx Pharmaceutical said on Monday late-stage studies showed its experimental drug for a type of genetic bone disease failed to reduce the number of fractures that occurred per year. Shares of ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...